NIH | National Cancer Institute | NCI Wiki  

Date

Attendees

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X

Musk, Philip (NIH/NCI) [C]

X
Warren KibbeX
Kim, Erika (NIH/NCI) [E]
X
Gregory TawaX
William Hendriks
X
Matthew Breen
X
Roel VerhaakX



Goals

  • Review, discuss, and prioritize ICDC study submission proposals

Outstanding Action items

  • Matthew & Warren to write an email request to Toby pertaining to formalization of a business plan for ICDC.
  • Musk, Philip (NIH/NCI) [C] to brush up on Nanostring documentation.

Agenda

Discussion ItemWhoNotes
New data submission request

Kuffel, Gina (NIH/NCI) [C] 

Data submission approved by Senior Advisory Committee

Kuffel, Gina (NIH/NCI) [C] 

  • "Immune Pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma" 
  • Data Submission Folder: OSA-Normal
  • Onboarding meeting set up with submitters
  • Study will be called OSA02
PRECINCT Data Request Submission: Inhaled IL-15 Immunotherapy for Treatment of Lung Metastases

All

  • PRECINCT SharePoint submission folder
  • PRECINCT Publication
  • Recently met with UC Davis team to demo the ICDC and discuss next steps for ingesting additional data.
Review of other Modiano publications: Other Modiano Publication Considerations.xlsx

Kuffel, Gina (NIH/NCI) [C]

Study Updates

Musk, Philip (NIH/NCI) [C]

  • TCL01
    • Study identifier changed to TCL01 (Tumor Cell Line)
    • Testing completed
    • Pending release record available on production
    • Still waiting on 6 study files
  • PRECINCT
    • Program now available on lower tier (dev environment)
    • Study record is in place
    • Working on Adverse Event node
    • Need follow-up call 
  • PANCAN01 (15 TB Re-analysis)
    • Data is already in a ICDC S3 bucket
    • Template-driven study onboarding initiated
    • One study will be onboarded at a time
    • Need to determine which study will be ingested first
  • OSA02
    • Onboarding meeting scheduled for Thursday

Minutes (Not Verbatim)

**Discussion of Q&A email thread with data submitters of Tissue & Organoid study**

GT- Some science associated with cancer and IBD, evident link but not an expert in this area.

PM - The submission seems to be more about IBD than it is about cancer based on our discussion

RV - Is this a good fit for our data repo? Would sending it away prevent this data from ever being made accessible to the public?

RV - How many of the patient samples will ultimately have omics data associated with them?

WK - Struggling with the strong rationale to import this data. 

EK - Need metadata for the cancer related samples.

WK - Is there a place where these organoids can be validated and made available for other researchers?

GT - There are members of the SC that can help with depositing samples to and getting samples from, Christine Mazcko is our contact.

RV - The submission is beyond the scope of our resource, however we should help to make this data available.

GT - What is their plan is to have genomic coverage for all individuals?

WK - In favor of finding a way to accept.

EK - Potentially leverage resources from DCTD, looks like their grant involves drug development for bladder cancer.

WK - Moving into the drug screening space would be valuable.

Action items